Kairos Pharma collaborates with Bayer to test ENV-105 + XOFIGO in mCRPC; market up to $1.3B

Kairos Pharma, LTD.

Bayer to supply radium for Kairos' study of ENV-105 (carotuximab) with XOFIGO in metastatic castration-resistant prostate cancer.
Prior Phase 2 data showed 86% clinical benefit rate and median PFS >13 months in resistant mCRPC.
Addressable global market estimated at $570M–$1.3B.
ENV-105 targets CD105 to re-sensitize tumors; XOFIGO is FDA-approved alpha-emitting radiopharmaceutical.
Collaboration includes customary terms; Kairos responsible for study financing and management.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.